New Treatments and Drugs on the Horizon for Alzheimer’s Dementia

On-Demand Video Session
Recorded from 2017 Western Pharmacy Exchange


Janice Hoffman, PharmD, Western University of Health Sciences

By the year 2050, the literature estimates a surge of patients with Alzheimer’s-type dementia to be more than 135 million in the United States. Currently, there are only a handful of agents approved for the treatment of Alzheimer’s Dementia. Research has identified several targeted hypothesis for new drug development. In 2017-18 there are likely 2 to 4 agents that will be added to the marketplace for the treatment of Alzheimer’s Disease including a vaccine to decrease Tau protein in the brain and a monoclonal antibody to decrease beta-amyloid deposits.

Learning Objectives
At the completion of this activity, the participant will be able to:

  1. Identify the 6 types of Dementia.
  2. Compare and contrast the currently available medications to the prosed new agents.
  3. Explain the proposed agents benefits to the therapy arsenal for Alzheimers.

Continuing Pharmacy Education
The California Pharmacists Association (#0113) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Upon completing an evaluation form, participants will be awarded 1.25 hours (0.125 CEUs) of Continuing Pharmacy Education Credit. A statement of credit will not be issued. Participants may log onto the CPE monitor website using their individual log in to download their statement of credit. Please allow 4 weeks for processing of CPE credits to the CPE monitor. UAN:  0113-0000-17-006-H04-P, 0113-0000-17-006-H04-T

Activity Type:  Knowledge-based
Target Audience:  Pharmacists and Technicians in all practice settings
Release Date: 1/5/2017
Expiration Date: 1/5/2020

CPhA Member – $49
Non-member – $99



  2017 Western Pharmacy Exchange Bundle Deal: $300
This session is one of 11 sessions in the bundle deal.
Purchase Bundle >

< Back to On Demand Video List